Jangseong Gun

Researchers are examining how different target levels of low-density lipoprotein (LDL) cholesterol affect patients who have had a small vessel occlusion (SVO) stroke, a type of ischemic stroke. The study addresses a gap in current stroke guidelines, which do not clearly define optimal LDL-cholesterol targets for different stroke types, especially for SVO stroke where hypertension is a major risk factor but high LDL-cholesterol may also contribute. This trial aims to improve secondary prevention by comparing intensive versus standard lipid-lowering therapies in adults with confirmed SVO stroke within 180 days of starting the study. Participants will be randomly assigned to one of two groups: an intensive treatment group targeting LDL-cholesterol levels under 70 mg/dL, or a standard treatment group targeting LDL levels between 90 and 110 mg/dL. Treatments include statins with or without ezetimibe, and if necessary, PCSK9 inhibitors to help achieve these LDL-cholesterol goals. The study plans to enroll 4,016 participants from multiple centers and will follow them for at least four years to monitor cardiovascular health outcomes. During the study, participants will have their LDL-cholesterol levels regularly checked and receive lipid-lowering therapies adjusted as needed to meet their target. Researchers will monitor major adverse cardiovascular events such as cardiovascular death, stroke recurrence, and acute coronary syndrome over the follow-up period. Participants must consent to the study and be available for long-term follow-up, which will provide important data to guide optimal cholesterol management for SVO stroke patients.

Researchers are evaluating the overall survival of women with stage I epithelial ovarian cancer following comprehensive staging surgery. This phase III trial compares the effects of adjuvant chemotherapy versus observation without chemotherapy in this patient group. Patients are randomly assigned based on histologic type, enrollment facility, and clinical staging according to the FIGO system. Participants are divided into two groups. Group A receives adjuvant chemotherapy, which includes either Paclitaxel plus Carboplatin or Docetaxel plus Carboplatin, administered every three weeks for three to six cycles. Switching between paclitaxel and docetaxel is allowed if adverse events occur. Group B undergoes observation only, with no chemotherapy given. The study treatment starts within eight weeks after comprehensive staging surgery. During the study, participants undergo regular assessments to monitor survival status up to 60 months from randomization. Researchers collect data including clinical evaluations, imaging, and laboratory tests as needed. Safety is closely monitored, and participants provide informed consent before enrollment. The trial aims to determine whether adjuvant chemotherapy improves survival compared to observation alone in this patient population.

Researchers are evaluating the safety and effectiveness of atogepant, an approved oral medication, for preventing chronic or episodic migraine in Korean adult patients. Migraine is a neurological condition involving moderate to severe headaches often accompanied by nausea, vomiting, and sensitivity to light and sound. This study focuses on adults prescribed atogepant under routine clinical practice to better understand its impact in real-world settings. Participants will take atogepant oral tablets as prescribed by their doctors. The study plans to enroll approximately 3,000 adult patients in Korea who meet the criteria for treatment with atogepant. The treatment period lasts up to 12 weeks, during which participants will attend regular hospital or clinic visits consistent with their usual care. There is no expected additional burden beyond standard clinical practice. During the study, researchers will monitor participants for various safety outcomes, including serious and non-serious adverse events, drug reactions, and any unexpected side effects up to about 16 weeks. They will also assess treatment-related adverse events and reasons for treatment discontinuation. Follow-up includes routine assessments at clinical visits, aiming to capture comprehensive safety and effectiveness data over the study period.

This research aims to evaluate the effectiveness, safety, and tolerability of atogepant, a medicine approved for preventing migraine, when used to treat migraine attacks quickly. The study focuses on adults aged 18 to 75 years who have a history of moderate to severe migraine attacks. It includes a double-blind phase where neither participants nor doctors know who receives atogepant or placebo, followed by an open-label phase where everyone receives atogepant. The study is conducted at about 160 sites worldwide with around 1300 participants. Participants will receive both atogepant and placebo in a random sequence to treat qualifying migraine attacks during the double-blind phase. After treating four migraine attacks this way, participants will enter an open-label phase lasting until week 24, during which they will receive atogepant for any additional migraine attacks. Treatments are given as oral tablets. Throughout the study, participants will attend regular hospital or clinic visits and telephone check-ins. They will complete electronic diaries with questionnaires about their migraines and treatment effects. Medical assessments, blood tests, and monitoring for side effects will be conducted. The main outcome measured is the percentage of participants who experience freedom from pain two hours after taking the study medication for their first treated migraine attack, observed over about 16 weeks.